FlexGuard Official Website › Blog › Four Rows At 8 mg | The Bottom Of A Joint Panel

Four Rows At Eight Milligrams: Reading The Bottom Of A Joint Panel

By FlexGuard TeamLast updated September 20269 min read1784 wordsReading the label · Reviewed by Dr. Elizabeth Ortiz, MD

What the bottom of a supplement panel is for

Read any supplement panel from the top and the amounts fall away fast. The first row is usually most of the capsule, the second and third are a meaningful fraction, and then there is a tail.

On this carton the tail is four rows at exactly 8 mg each: quercetin, methionine, methylsulfonylmethane and bromelain. Together they are 32 mg, which is under five per cent of the 699 mg of actives in the capsule.

The four are worth reading as a group rather than one at a time, because they raise the same question four times and the answer is slightly different in each case. Two of them have a trial record at much larger amounts. One has no human joint trial at any amount. And one is not the molecule its reputation belongs to.

Four rows, four different kinds of gap. Only two of them are gaps in the ordinary sense of being a small version of something larger.

Quercetin at 8 mg: a number with nothing to compare it to

Quercetin is a flavonoid. Most people get some from onions, apples and tea; on this panel it comes from the bud of the Japanese pagoda tree, which is a common commercial source.

It has attracted genuine scientific interest in the last decade as a senolytic, meaning a compound that helps clear worn-out cells that have stopped dividing but have not been cleared away. Senescent cells are part of the current picture of how a joint ages, so the interest is not manufactured.

The pooled osteoarthritis evidence, though, is preclinical. It is animal models and laboratory work, and the review that collects it says so in its title. There is no randomised trial of quercetin in human joints at any amount.

That makes 8 mg an unusual number. It is not a fraction of a tested dose, because there is no tested dose. It is a number with nothing on the other side of the comparison, and the honest thing to say about it is exactly that.

Methionine at 8 mg: the precursor, not the compound

Methionine is an essential amino acid with a sulfur atom in it. It is in every protein-containing food you eat, and a normal day supplies well over a gram.

Its presence on a joint panel is not random. Methionine is the raw material the body uses to make S-adenosylmethionine, usually shortened to SAMe, and SAMe does have a joint record. A meta-analysis of SAMe in osteoarthritis looked at trials using 600 to 1,200 mg a day and compared it with anti-inflammatory drugs.

But SAMe is not methionine, any more than flour is bread. Supplying 8 mg of a precursor to a body already receiving more than a gram of it from lunch is not the same intervention as supplying 600 mg of the finished molecule, and no trial has tested the first.

This is the row where a reader is most likely to be misled by a search engine, because searching the name on the panel returns the literature belonging to a different compound.

MSM at 8 mg, against one and a half to six grams

Methylsulfonylmethane is an organosulfur compound, sold on the reasoning that it supplies sulfur the body uses in connective tissue.

It is one of the two rows in this group with a real human record. The 2017 review of it sets out how it is normally used, which is 1.5 to 6 grams a day. A 2023 trial in people with mild knee pain used 2 grams a day for twelve weeks and reported an improvement in knee-related quality of life. An earlier systematic review called the evidence promising and thin in the same breath, which is still a fair description.

Eight milligrams is roughly a two-hundred-and-fiftieth of that 2 gram amount. To put it in a shape that is easier to hold: you would need to take 250 of these capsules in a day to reach the MSM in that trial, and you would be taking 125 grams of glucosamine along with it.

That arithmetic is not an accusation. It is the reason a broad capsule and a single-ingredient product are different categories of purchase.

Bromelain at 8 mg, against two hundred and upwards

Bromelain is a mixture of protein-digesting enzymes from pineapple stem, used in Europe for decades in enzyme preparations given for swelling after injury.

Its joint evidence is the most interesting of the four and the least flattering to a small amount, because it is explicitly dose-dependent. An open study gave 200 mg and 400 mg a day and saw more at the higher amount, which is the shape of result that suggests something real is happening. A placebo-controlled pilot at 800 mg a day then failed to beat placebo, and a 16-week trial used 1,890 mg a day of a bromelain preparation.

So the published range runs from 200 mg to nearly 2 grams, with mixed results throughout it, and this row is 8 mg. When the evidence for an ingredient is explicitly dose-dependent, a small amount is harder to defend than it would be for an ingredient whose evidence is flat.

Three published amounts spanning a factor of nine, and a fourth row two orders of magnitude below all of them.

Why a formulator puts them there anyway

It would be easy to end a post like this by calling the bottom of the panel decoration, and easy is not the same as right. There are two defensible reasons a formulator includes a small amount.

The first is breadth. A capsule carrying eight ingredients touches more of the mechanisms people believe in than a capsule carrying one, and a buyer comparing two labels in a shop will very often pick the longer list. That is a commercial reason and it is an honest description of why the shelf looks the way it does.

The second is that some of these compounds have not been tested at low amounts either. Absence of evidence at 8 mg is not evidence of absence at 8 mg. It does mean that anyone claiming a benefit from these four rows is claiming something nobody has measured, and the seller of this product does not make that claim: the carton claims joint comfort and mobility for the formula as a whole.

• Breadth sells, and a longer ingredient list is a real commercial advantage.
• A small amount has usually not been tested, rather than tested and failed.
• A capsule has a fixed volume, and 699 mg is most of it.
• Four rows at 8 mg cost almost nothing and add four names to the front of the box.
• None of that is a claim the seller here is making.

How to work out what any row is worth in thirty seconds

The method that produced this post is short enough to describe, and it works on any label.

Take the row. Search the ingredient name with the word trial or the word meta-analysis, and find the amount that was administered. Divide. If the answer is between one and three you are looking at a tested amount or something near it. If it is in the tens you are looking at a fraction. If it is in the hundreds, the row is there for the front of the box.

Two traps make the method go wrong. The first is a precursor: searching methionine returns literature about a molecule the body makes from it, and dividing 8 mg by 600 mg is comparing two different substances. The second is standardisation: dividing a herb weight by an extract weight compares two different materials, which is why the Boswellia row higher up this panel cannot be divided at all.

Neither trap is exotic and both are common. A label that names a plant part and a weight, with no percentage, has given you a number you cannot use, and a label that names a precursor has given you a number belonging to something else.

The one thing the bottom of a panel does tell you

The bottom of a panel is where you find out whether a label is being straight with you, and this one is.

A proprietary blend would have pooled all eight of these rows into a single weight, listed the names in descending order, and told you nothing else. Under that arrangement 8 mg and 80 mg look identical from outside the bottle, and a reader has no way to write the post you are reading.

Printing 8 mg four times is a small act of honesty that costs a seller something, because it invites exactly this criticism. It is worth crediting while also saying plainly that four rows at 8 mg are not the reason to buy anything.

The full panel, and the four larger rows above these, are on the supplement facts page, with the trial amounts beside them on the ingredients page.